0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover633.65%IV-74.25%PremiumAug 16, 2024Expiry Date7.21Intrinsic Value100Multiplier24DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9492Delta0.0067Gamma--Leverage Ratio-0.0337Theta0.0008Rho0.00Eff Leverage0.0026Vega
Kyverna Therapeutics Stock Discussion
Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
Kyverna Therapeutics (KYTX) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for KYV-101, its autologous CD19 CAR T-cell therapy, in treating refractory stiff-person syndrome. This designation, based on positive clinical outcomes in Germany, allows Kyverna to receive expert guidance on efficient ...
No comment yet